<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="62139"><DrugName>lurbinectedin</DrugName><DrugNamesKey><Name id="43103735">Zepsyre</Name><Name id="42955515">lurbinectedin</Name></DrugNamesKey><DrugSynonyms><Name><Value>anticancer agents (natural product), PharmaMar</Value></Name><Name><Value>PM-01183</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PM-00113</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PM-01120</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PM-050489</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PM-1183</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>tryptamicidin</Value></Name><Name><Value>lurbinectedin</Value><Types><Type>INN</Type></Types></Name><Name><Value>Zepsyre</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>497871-47-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17927">PharmaMar SA</CompanyOriginator><CompaniesPrimary><Company id="1015499">Luye Pharma Group Ltd</Company><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Company id="17927">PharmaMar SA</Company><Company id="14987">Boryung Pharm Co Ltd</Company><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="15414">Chugai Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="62139" type="Drug"><TargetEntity id="655855" type="siDrug">Lurbinectedin</TargetEntity></SourceEntity><SourceEntity id="1015499" type="Company"><TargetEntity id="4295887822" type="organizationId">Luye Pharma Group Ltd</TargetEntity></SourceEntity><SourceEntity id="1044298" type="Company"><TargetEntity id="5035525776" type="organizationId">Specialised Therapeutics Australia Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="1157003" type="Company"><TargetEntity id="5056200653" type="organizationId">Specialised Therapeutics Asia Pte Ltd</TargetEntity></SourceEntity><SourceEntity id="14987" type="Company"><TargetEntity id="4295880912" type="organizationId">Boryung Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="15414" type="Company"><TargetEntity id="4295876884" type="organizationId">Chugai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="17927" type="Company"><TargetEntity id="5000066579" type="organizationId">Pharma Mar SA</TargetEntity></SourceEntity><SourceEntity id="1240" type="ciIndication"><TargetEntity id="C45" type="ICD10"></TargetEntity><TargetEntity id="163" type="ICD9"></TargetEntity><TargetEntity id="10027406" type="MEDDRA"></TargetEntity><TargetEntity id="D008654" type="MeSH"></TargetEntity><TargetEntity id="50251" type="ORPHANET"></TargetEntity><TargetEntity id="-666440137" type="omicsDisease"></TargetEntity><TargetEntity id="2015" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1261" type="ciIndication"><TargetEntity id="10041056" type="MEDDRA"></TargetEntity><TargetEntity id="D055752" type="MeSH"></TargetEntity><TargetEntity id="70573" type="ORPHANET"></TargetEntity><TargetEntity id="-1257831198" type="omicsDisease"></TargetEntity><TargetEntity id="614" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1515" type="ciIndication"><TargetEntity id="D001650" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="1705" type="ciIndication"><TargetEntity id="10014733" type="MEDDRA"></TargetEntity><TargetEntity id="D016889" type="MeSH"></TargetEntity><TargetEntity id="-49801714" type="omicsDisease"></TargetEntity><TargetEntity id="597" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1727" type="ciIndication"><TargetEntity id="10000830" type="MEDDRA"></TargetEntity><TargetEntity id="684" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"></TargetEntity><TargetEntity id="D019337" type="MeSH"></TargetEntity><TargetEntity id="-105358819" type="omicsDisease"></TargetEntity><TargetEntity id="1328" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2975" type="ciIndication"><TargetEntity id="10015560" type="MEDDRA"></TargetEntity><TargetEntity id="D012512" type="MeSH"></TargetEntity><TargetEntity id="319" type="ORPHANET"></TargetEntity><TargetEntity id="-1966079594" type="omicsDisease"></TargetEntity><TargetEntity id="1349" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"></TargetEntity><TargetEntity id="589" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3669" type="ciIndication"><TargetEntity id="631" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3672" type="ciIndication"><TargetEntity id="10055114" type="MEDDRA"></TargetEntity><TargetEntity id="2341" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3737" type="ciIndication"><TargetEntity id="D009373" type="MeSH"></TargetEntity><TargetEntity id="-720598874" type="omicsDisease"></TargetEntity><TargetEntity id="603" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="623" type="ciIndication"><TargetEntity id="C76.0" type="ICD10"></TargetEntity><TargetEntity id="10067821" type="MEDDRA"></TargetEntity><TargetEntity id="D006258" type="MeSH"></TargetEntity><TargetEntity id="-545944758" type="omicsDisease"></TargetEntity><TargetEntity id="1148" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="755" type="ciIndication"><TargetEntity id="C34" type="ICD10"></TargetEntity><TargetEntity id="10062042" type="MEDDRA"></TargetEntity><TargetEntity id="D008175" type="MeSH"></TargetEntity><TargetEntity id="-243902424" type="omicsDisease"></TargetEntity><TargetEntity id="611" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="359" type="Action"><TargetEntity id="2996" type="Mechanism">Anti-TAT</TargetEntity><TargetEntity id="498" type="Mechanism">Tat Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="11593" type="Action"><TargetEntity id="3104" type="Mechanism">DNA Repair Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="PTGT-01817" type="ciTarget"><TargetEntity id="9627975741558713" type="siTarget">Trans-Activator of Transcription Human immunodeficiency virus 1</TargetEntity><TargetEntity id="-1656964626" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1240">Mesothelioma</Indication><Indication id="1261">Small-cell lung cancer</Indication><Indication id="1515">Biliary tumor</Indication><Indication id="1705">Endometrioid carcinoma</Indication><Indication id="1727">Acute leukemia</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="2975">Ewing sarcoma</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="3669">Metastatic pancreas cancer</Indication><Indication id="3672">Metastatic colon cancer</Indication><Indication id="3737">Germ cell and embryonic cancer</Indication><Indication id="623">Head and neck tumor</Indication><Indication id="725">Solid tumor</Indication><Indication id="799">Ovary tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="651">Cancer</Indication><Indication id="755">Lung tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="6827">RNA polymerase II inhibitor</Action><Action id="359">TAT protein inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="11593">DNA repair inhibitor</Action><Action id="1545">Anticancer</Action><Action id="1589">Apoptosis stimulator</Action><Action id="7293">Synergist</Action></ActionsSecondary><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-29T09:16:17.000Z</LastModificationDate><ChangeDateLast>2019-06-28T00:00:00.000Z</ChangeDateLast><AddedDate>2008-12-30T12:43:03.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17927" linkType="Company"&gt;PharmaMar&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="27906" linkType="Company"&gt;Zeltia&lt;/ulink&gt;) is developing   lurbinectedin (Zepsyre, PM-01183, PM-1183, tryptamicidin, structure shown), an RNA polymerase II inhibitor and the lead from a  series of synthetic alkaloid ecteinascidin derivatives which bind  to the minor groove of DNA and promote apoptosis,  for the potential iv treatment of  solid tumors including pancreatic cancer, ovarian cancer, lung cancer, breast cancer, small cell lung cancer (SCLC), colon cancer and Ewing sarcoma, endometrial cancer, biliary tract carcinoma and hematological cancers including leukemia  [&lt;ulink linkID="973340" linkType="Reference"&gt;973340&lt;/ulink&gt;], [&lt;ulink linkID="1146120" linkType="Reference"&gt;1146120&lt;/ulink&gt;], [&lt;ulink linkID="1319184" linkType="Reference"&gt;1319184&lt;/ulink&gt;], [&lt;ulink linkID="1539212" linkType="Reference"&gt;1539212&lt;/ulink&gt;], [&lt;ulink linkID="1491290" linkType="Reference"&gt;1491290&lt;/ulink&gt;], [&lt;ulink linkID="1606714" linkType="Reference"&gt;1606714&lt;/ulink&gt;], [&lt;ulink linkID="1666381" linkType="Reference"&gt;1666381&lt;/ulink&gt;], [&lt;ulink linkID="1887758" linkType="Reference"&gt;1887758&lt;/ulink&gt;], [&lt;ulink linkID="1938446" linkType="Reference"&gt;1938446&lt;/ulink&gt;]. In July 2016, PharmaMar initiated a phase III trial in patients with relapsed small-cell lung cancer (SCLC)  [&lt;ulink linkID="1784693" linkType="Reference"&gt;1784693&lt;/ulink&gt;]; in June 2018, top line data were expected  in second half of 2019 [&lt;ulink linkID="2043770" linkType="Reference"&gt;2043770&lt;/ulink&gt;]. In May 2015, a phase III trial for ovarian cancer  was  initiated  [&lt;ulink linkID="1653269" linkType="Reference"&gt;1653269&lt;/ulink&gt;]. In June 2011, a phase II trial in metastatic pancreatic cancer was initiated [&lt;ulink linkID="1205988" linkType="Reference"&gt;1205988&lt;/ulink&gt;]. In November 2011, a phase II study in advanced ovarian cancer was ongoing [&lt;ulink linkID="1252455" linkType="Reference"&gt;1252455&lt;/ulink&gt;]; by May 2013, a phase IIb trial for resistant/refractory ovarian cancer had been initiated [&lt;ulink linkID="1416459" linkType="Reference"&gt;1416459&lt;/ulink&gt;]. By August 2012, a phase II trial for lung cancer had been initiated [&lt;ulink linkID="1319184" linkType="Reference"&gt;1319184&lt;/ulink&gt;].   By June 2012, a phase II metastatic breast cancer trial had been initiated [&lt;ulink linkID="1309233" linkType="Reference"&gt;1309233&lt;/ulink&gt;].    In July 2015, a  phase II trial was initiated in patients with advanced solid tumors including breast cancer, endometrial carcinoma, biliary tract cancer, ewing sarcoma and germ cell tumros in the US and Europe [&lt;ulink linkID="1676326" linkType="Reference"&gt;1676326&lt;/ulink&gt;]; in June 2018, data were presented [&lt;ulink linkID="2039906" linkType="Reference"&gt;2039906&lt;/ulink&gt;]. in October 2018, trial was expected to complete in January 2020   [&lt;ulink linkID="1676326" linkType="Reference"&gt;1676326&lt;/ulink&gt;]. A phase I trial in acute leukemia began in May 2011 [&lt;ulink linkID="1205863" linkType="Reference"&gt;1205863&lt;/ulink&gt;]. In May 2013, a phase Ib, &lt;ulink linkID="12205" linkType="Drug"&gt;capecitabine&lt;/ulink&gt; combination trial began in unresectable metastatic breast cancer, pancreatic cancer and metastatic colon cancer [&lt;ulink linkID="1427626" linkType="Reference"&gt;1427626&lt;/ulink&gt;]; in September 2014, data were presented   [&lt;ulink linkID="1597517" linkType="Reference"&gt;1597517&lt;/ulink&gt;].     In November 2016, an open-label, multi-center, phase I trial was initiated in  patients with solid tumors, in Japan [&lt;ulink linkID="1878529" linkType="Reference"&gt;1878529&lt;/ulink&gt;]. In June 2017, PharmaMar planned to initiate pivotal phase III trials in BRCA 2-associated metastatic breast cancer and endometrial cancer [&lt;ulink linkID="1938446" linkType="Reference"&gt;1938446&lt;/ulink&gt;]. In June 2017, the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC) of the FDA invited the company to present the background information on Zepsyre, positive clinical data obtained from phase I and II trials, in which a good tolerance and a good safety profile were observed, and to assess the potential role of the drug in pediatric cancers and hematological disorders [&lt;ulink linkID="1939106" linkType="Reference"&gt;1939106&lt;/ulink&gt;]. In September 2018, a proof of concept phase II trial in mesothelioma was initiated in Italy and Switzerland in collaboration with &lt;ulink linkID="1041703" linkType="Company"&gt;The Swiss Group for Clinical Cancer Research&lt;/ulink&gt;  [&lt;ulink linkID="2105352" linkType="Reference"&gt;2105352&lt;/ulink&gt;]; in December 2018,  data were expected in early  2019 [&lt;ulink linkID="2105291" linkType="Reference"&gt;2105291&lt;/ulink&gt;]. In April 2019, licensee &lt;ulink linkID="1015499" linkType="Company"&gt;Luye Pharma&lt;/ulink&gt; planned  to develop the drug in SCLC in China [&lt;ulink linkID="2146288" linkType="Reference"&gt;2146288&lt;/ulink&gt;]. In March 2012, PharmaMar was seeking to outlicense the drug in the US and Japan [&lt;ulink linkID="1289310" linkType="Reference"&gt;1289310&lt;/ulink&gt;]. In June 2018, PharmaMar was seeking to outlicense the drug again in Japan following termination of the agreement with Chugai [&lt;ulink linkID="2048984" linkType="Reference"&gt;2048984&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;PharmaMar Japan licensee &lt;ulink linkID="15414" linkType="Company"&gt;Chugai&lt;/ulink&gt; was developing   lurbinectedin   for the potential treatment of  solid tumors  [&lt;ulink linkID="1887758" linkType="Reference"&gt;1887758&lt;/ulink&gt;].     In November 2016, an open-label, multi-center, phase I trial was initiated in  patients with solid tumors, in Japan [&lt;ulink linkID="1878529" linkType="Reference"&gt;1878529&lt;/ulink&gt;].In December 2016, Chugai planned to file the program in Japan  [&lt;ulink linkID="1887758" linkType="Reference"&gt;1887758&lt;/ulink&gt;]. However, in June 2018, the companies entered a mutual early termination agreement; PharmaMar regained all its rights for the drug in Japan and would continue development in the territory [&lt;ulink linkID="2048984" linkType="Reference"&gt;2048984&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company was previously developing the drug for the potential treatment of non-small cell lung cancer (NSCLC). In October 2014, a phase II study in  NSCLC patients was initiated. In November 2016, trial was completed   [&lt;ulink linkID="1487633" linkType="Reference"&gt;1487633&lt;/ulink&gt;].   However, no further development has been reported for this indication since that time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2018, the FDA granted Orphan Drug Designation to lurbinectedin for the treatment of small cell lung cancer [&lt;ulink linkID="2060016" linkType="Reference"&gt;2060016&lt;/ulink&gt;], [&lt;ulink linkID="2064368" linkType="Reference"&gt;2064368&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2012, the FDA granted lurbinectedin Orphan Drug designation for the treatment of ovarian cancer [&lt;ulink linkID="1319184" linkType="Reference"&gt;1319184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September 2012, the EMA's COMP issued a positive opinion for Orphan Drug status for the treatment of ovarian cancer [&lt;ulink linkID="1321660" linkType="Reference"&gt;1321660&lt;/ulink&gt;], [&lt;ulink linkID="1323703" linkType="Reference"&gt;1323703&lt;/ulink&gt;]; in October 2012, Orphan status was granted [&lt;ulink linkID="1339954" linkType="Reference"&gt;1339954&lt;/ulink&gt;]. In January 2019, the EMA's COMP issued a positive opinion for Orphan Drug status for the treatment of small cell lung cancer [&lt;ulink linkID="2113811" linkType="Reference"&gt;2113811&lt;/ulink&gt;], [&lt;ulink linkID="2115286" linkType="Reference"&gt;2115286&lt;/ulink&gt;]; in February 2019, the Orphan designation was granted [&lt;ulink linkID="2135892" linkType="Reference"&gt;2135892&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In November 2017, it was stated that licensee &lt;ulink linkID="14987" linkType="Company"&gt;Boryung Pharm&lt;/ulink&gt; was to market the drug, if approved, in South Korea [&lt;ulink linkID="1978834" linkType="Reference"&gt;1978834&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Mesothelioma&lt;/subtitle&gt;In September 2018, an open-label, prospective, two-stage, single-arm, multi-center, proof of concept phase II trial (&lt;ulink linkID="305061" linkType="Protocol"&gt;NCT03213301&lt;/ulink&gt;; SAKK 17/16; 2017-001016-11) to evaluate the efficacy and tolerability of lurbinectedin monotherapy in progressive malignant pleural mesothelioma was initiated in Italy and Switzerland in collaboration with &lt;ulink linkID="1041703" linkType="Company"&gt;The Swiss Group for Clinical Cancer Research&lt;/ulink&gt; (SAKK).  The primary endpoint was to determine the  progression free survival (PFS) at 12 weeks. At that time, the trial was expected to complete in March 2022 [&lt;ulink linkID="2105352" linkType="Reference"&gt;2105352&lt;/ulink&gt;]. In October 2018, study design was presented at 2018 ESMO Congress in Munich, Germany. Patients (n = 43) received lurbinectedin 3.2 mg/m2 iv q3w (one cycle) until progression. At that time, 32 patients were enrolled [&lt;ulink linkID="2084488" linkType="Reference"&gt;2084488&lt;/ulink&gt;]. In December 2018, patient (n = 42) recruitment  was completed. At that time, data were expected in early  2019 [&lt;ulink linkID="2105291" linkType="Reference"&gt;2105291&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;NSCLC&lt;/subtitle&gt;In September 2013, the company planned to initiate a randomized, controlled, three-arm, efficacy phase II study (&lt;ulink linkID="156258" linkType="Protocol"&gt;NCT01951157&lt;/ulink&gt;; PM1183-B-004-13) of lurbinectedin  alone or in combination with gemcitabine and a control arm with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; as second-line treatment, in unresectable NSCLC patients (expected n = 120) in November 2013. At that time, the trial was expected to complete in December 2015 [&lt;ulink linkID="1487633" linkType="Reference"&gt;1487633&lt;/ulink&gt;]. In October 2014, the trial was initiated [&lt;ulink linkID="1487633" linkType="Reference"&gt;1487633&lt;/ulink&gt;]. In November 2016, trial was completed [&lt;ulink linkID="1487633" linkType="Reference"&gt;1487633&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2012, a phase II trial for lung cancer had been initiated [&lt;ulink linkID="1319184" linkType="Reference"&gt;1319184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic breast cancer&lt;/subtitle&gt;In February 2017, a pivotal phase III trial was planned to be initiated [&lt;ulink linkID="1903469" linkType="Reference"&gt;1903469&lt;/ulink&gt;]. In July 2017, the trial was expected to begin in the fourth quarter of 2017 [&lt;ulink linkID="1949200" linkType="Reference"&gt;1949200&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2012, an open-label, phase II study (&lt;ulink linkID="84579" linkType="Protocol"&gt;NCT01525589&lt;/ulink&gt;; PM1183-B-003-11) was planned in patients with BRCA 1/2-associated or unselected metastatic breast cancer (expected n = 117) in the US, to assess the efficacy of lurbinectedin. At that time, the study was scheduled to begin in March 2012, and complete in March 2015 [&lt;ulink linkID="1261193" linkType="Reference"&gt;1261193&lt;/ulink&gt;]; by June 2012, the trial had been initiated inthe US and Spain  [&lt;ulink linkID="1309233" linkType="Reference"&gt;1309233&lt;/ulink&gt;]. In December 2013, it was reported at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, in San Antonio, TX that  36 patients had been enrolled [&lt;ulink linkID="1512938" linkType="Reference"&gt;1512938&lt;/ulink&gt;]. In October 2016, clinical data of 56 patients were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Of 51 evaluable patients, 1, 19, 22 and 9 patients achieved complete response, partial response, stable disease and progressive disease, respectively.  Overall response rate (ORR; primary endpoint) by RECIST v1.1 was 39% (37/44% for 7 mg fixed dose/3.5 mg/m2). In platinum pre-treated patients, ORR was 23%. Median duration of response and progression-free survival was 4.6 and 4.1+ months, respectively [&lt;ulink linkID="1805799" linkType="Reference"&gt;1805799&lt;/ulink&gt;] [&lt;ulink linkID="1805447" linkType="Reference"&gt;1805447&lt;/ulink&gt;].  In June 2017, further clinical data from exploratory analysis were presented at the 53rd ASCO meeting in Chicago, IL. The duration of response and progression free survival was 10.2 and 3 months (germline BRCA1), 6.4 and 6 months (germline BRCA2), respectively. The some of treatment related adverse events reported in &amp;gt;/= 5% patients were febrile neutropenia, nausea, constipation, vomiting, abdominal pain, diarrhea, mucositis, anorexia, fatigue, dyspnea, pyrexia and headache [&lt;ulink linkID="1932206" linkType="Reference"&gt;1932206&lt;/ulink&gt;]. In October 2018, trial was active but not recruiting the patients [&lt;ulink linkID="1261193" linkType="Reference"&gt;1261193&lt;/ulink&gt;].  In November 2018, data were published. Data demonstrated overall response rate (ORR) of 61%,   median progression-free survival (PFS) of  5.9 months and  median overall survival (OS) of 26.6 months. An highest ORR of 72% was ovserved in untreated PARP population [&lt;ulink linkID="2093295" linkType="Reference"&gt;2093295&lt;/ulink&gt;], [&lt;ulink linkID="2093674" linkType="Reference"&gt;2093674&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ovarian cancer&lt;/subtitle&gt;In September 2013, the company planned to initiate a pivotal phase III trial in platinum-resistant ovarian cancer [&lt;ulink linkID="1476983" linkType="Reference"&gt;1476983&lt;/ulink&gt;]. In April 2015, an open-label, randomized, controlled, multicenter, phase III trial (&lt;ulink linkID="227222" linkType="Protocol"&gt;NCT02421588&lt;/ulink&gt;; PM1183-C-004-14; CORAIL) was  planned to be initiated, in patients (expected n = 420) with ovarian cancer, to assess the safety and efficacy of lurbinectedin compared to &lt;ulink linkID="7934" linkType="Drug"&gt;pegylated liposomal doxorubicin&lt;/ulink&gt; or &lt;ulink linkID="4577" linkType="Drug"&gt;topotecan&lt;/ulink&gt;. At that time, the trial was expected to complete in October 2018. In May  2015, the trial was initiated in the US [&lt;ulink linkID="1653269" linkType="Reference"&gt;1653269&lt;/ulink&gt;]. In June 2015, first patient was enrolled in the US and the trial was also planned to enroll patients in Europe [&lt;ulink linkID="1673894" linkType="Reference"&gt;1673894&lt;/ulink&gt;]. In February 2016, Independent Data Monitoring Committee (IDMC) recommended the continuation of the CORAIL study without any changes after  analysis of the safety data obtained from the first 80 patients treated [&lt;ulink linkID="1733143" linkType="Reference"&gt;1733143&lt;/ulink&gt;]. In August 2016, the company received approval from the  IDMC to continue the trial [&lt;ulink linkID="1787292" linkType="Reference"&gt;1787292&lt;/ulink&gt;]. In October 2016, a total of 443 patients were enrolled in the trial from more than 100 hospitals from Europe and the US [&lt;ulink linkID="1864303" linkType="Reference"&gt;1864303&lt;/ulink&gt;]. In February 2017, data from the trial were expected in the second half of 2017 [&lt;ulink linkID="1903469" linkType="Reference"&gt;1903469&lt;/ulink&gt;]. In July 2017, data from the trial were expected by the early 2018 [&lt;ulink linkID="1949200" linkType="Reference"&gt;1949200&lt;/ulink&gt;]. In January 2018,  data  were reported. The drug did not meet the primary endpoint of PFS.  The antitumoral activity of the three compounds Zepsyre, topotecan and PLD, in terms of PFS, were the same. Zepsyre  demonstrated a better safety profile than the control arm [&lt;ulink linkID="1998574" linkType="Reference"&gt;1998574&lt;/ulink&gt;]. In October 2018, further data from this trial were presented at the 2018 ESMO Congress in Munich, Germany. The PFS in the lurbinectedin and control arms were 3.5 and 3.6 months, respectively (HR = 1.04), with no improvements for lurbinectedin versus controls groups noted in any subgroup analyses, including BRCA mutations, prior bevacizumab and histology type. No improvements in overall survival  (11.2 versus 11.1 months; HR = 0.97) or overall response rate (14 versus 12.2%) were reported. Furthermore, there were no improvements over control in PFS, OS or response rate in patients with primary or secondary platinum resistance [&lt;ulink linkID="2084704" linkType="Reference"&gt;2084704&lt;/ulink&gt;], [&lt;ulink linkID="2085414" linkType="Reference"&gt;2085414&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, phase II development for platinum-resistant/refractory ovarian cancer was underway [&lt;ulink linkID="1336034" linkType="Reference"&gt;1336034&lt;/ulink&gt;]. The open-label, randomized, phase IIb trial ((PM-01183-B-002-11)  was to evaluate PM-01183 compared with topotecan  in patients with resistant/refractory ovarian cancer. By May 2013, enrollment was completed. Patients would be treated with 7 mg flat dose q3 week in the first stage, while in the second stage patients were randomized to lurbinectedin or topotecan. Crossover to lurbinectedin was allowed if patients progressed on topotecan [&lt;ulink linkID="1416459" linkType="Reference"&gt;1416459&lt;/ulink&gt;]. In September 2012,  data were   presented from the first stage of the study at the 37th Congress of the European Society for Medical Oncology  in Vienna, Austria. The overall response rate and disease control rate was 27 and 73%, respectively, and the median progression free survival (PFS) was 4 months [&lt;ulink linkID="1325969" linkType="Reference"&gt;1325969&lt;/ulink&gt;]. In September 2013, topline results from the second stage of the trial were reported demonstrating that 30.3% of platinum-resistant patients had an objective response in the lurbinectedin arm compared to the topotecan arm. Clinical benefit of 82 and 50% was observed with patients in the PM-01183 and  topotecan arm, respectively. The respective median progression-free survival was 4.8 and 1.7 months [&lt;ulink linkID="1476983" linkType="Reference"&gt;1476983&lt;/ulink&gt;]. In June 2015, further data were reported. Data demonstrated that PM-1183 showed PFS of 5.7 months compared to 1.7 months for topotecan [&lt;ulink linkID="1673894" linkType="Reference"&gt;1673894&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic pancreatic cancer&lt;/subtitle&gt;In June 2011,  a single-arm exploratory  phase II trial of lurbinectedin as a second-line treatment, in patients with exocrine metastatic pancreatic cancer for which standard therapy has failed,  was initiated. The primary endpoint was 6-month overall survival, in an estimated 43 evaluable patients in Spain and the UK [&lt;ulink linkID="1205988" linkType="Reference"&gt;1205988&lt;/ulink&gt;], [&lt;ulink linkID="1210499" linkType="Reference"&gt;1210499&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumor&lt;/subtitle&gt; &lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2016, study design of first-in-human, phase I/II study (&lt;ulink linkID="253882" linkType="Protocol"&gt;NCT02684318&lt;/ulink&gt;) which evaluates safety and tolerability of PM-1183 in combination with short course of &lt;ulink linkID="16063" linkType="Drug"&gt;olaparib&lt;/ulink&gt; through a 3 + 3 escalating doses in patients with advanced solid tumors was presented at the ESMO 2016 Congress in Copenhagen, Denmark. Primary endpoint of phase I study was safety (MTD, DLT and recommended phase II dose) and phase II study was overall response rate. At the end of April 2016, the trial was in progress and 13 patients were enrolled in phase I part (expected n = 48; enrollment was started in November 2015)  [&lt;ulink linkID="1805734" linkType="Reference"&gt;1805734&lt;/ulink&gt;]. In June 2017, clinical data from 20 patients were presented at the 53rd ASCO meeting in Chicago, IL. At 2 mg/m2 dose of PM-01183 and 250 mg/m2 dose of olaparib, two DLTs were reported (grade 4 neutropenia; primary objective). The median time to clearance (secondary objective) of PM-01183 (11 l/h) was similar to PM-01183 as single agent. The recommended phase II dose of PM-01183 and olaparib were 1.5 mg/m2 (iv, day-1) and 250 mg (bid, day 1 to 5), respectively  [&lt;ulink linkID="1932433" linkType="Reference"&gt;1932433&lt;/ulink&gt;], [&lt;ulink linkID="1937328" linkType="Reference"&gt;1937328&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, trial design about a multicenter, phase II trial (BASKET) in selected advanced solid tumors patients (expected n = 135) were presented  at the 51st ASCO meeting in Chicago, IL. Patients would receive lurbinectedin (3.2 mg/m2 q3w) as iv infusion for 1 h. A total of 26 centers in 8 countries  participated in this trial [&lt;ulink linkID="1664745" linkType="Reference"&gt;1664745&lt;/ulink&gt;]. In July 2015, a multicenter, phase II trial (&lt;ulink linkID="230584" linkType="Protocol"&gt;NCT02454972&lt;/ulink&gt;; PM1183-B-005-14) was initiated in the US in patients (expected n = 225) with solid tumors. The trial was expected to complete in July 2019 [&lt;ulink linkID="1676326" linkType="Reference"&gt;1676326&lt;/ulink&gt;]. In September 2015, the first patient was enrolled in an open-label, international, exploratory, BASKET trial to assess the safety, efficacy, pharmacological profile, pharmacogenetic and pharmacogenomics analysis of  in advanced solid tumors including  small cell lung cancer (SCLC), head and neck cancer, neuroendocrine tumors (NETs), biliary tract tumors, endometrial cancer, BRCA 1/2-associated breast cancer, germ cell tumors and Ewing's family of tumors in the US and Europe [&lt;ulink linkID="1695732" linkType="Reference"&gt;1695732&lt;/ulink&gt;]. In September 2017, clinical data were presented at the ESMO 2017 Congress in Madrid, Spain. PR was achieved by 13 patients, ORR was achieved by 13 patients, SD was observed in 14 patients, PD was observed in 9 patients, DCR was achieved by 27 patients, DOR was 6.2+ months, PFS in patients with CTFI &amp;gt; 30 days and platinum-sensitive  patients was 3.1+ and 4.6+ months, respectively[&lt;ulink linkID="1960731" linkType="Reference"&gt;1960731&lt;/ulink&gt;],[&lt;ulink linkID="1957802" linkType="Reference"&gt;1957802&lt;/ulink&gt;], [&lt;ulink linkID="1961482" linkType="Reference"&gt;1961482&lt;/ulink&gt;], [&lt;ulink linkID="1961385" linkType="Reference"&gt;1961385&lt;/ulink&gt;]. In November 2017, results from the trial in patients with Ewing's sarcoma were presented at the Connective Tissue Oncology Society´s (CTOS) International Congress in Wailea, HI. The trial had enrolled 25 patients with Ewing´s sarcoma. Data demonstrated that the observed disease control rate (overall response, partial response and stabilization of the disease) was 60%, including partial responses in 12% of cases, and a stabilization of the disease in the 48% of cases. Also, observed median duration of response was 2.9 months and 3 months of median progression free survival was reached. The study also highlighted that new therapeutic agents with different mechanism of action were needed in 	patients with advanced Ewing´s sarcoma [&lt;ulink linkID="1981601" linkType="Reference"&gt;1981601&lt;/ulink&gt;]. In June 2018, further data from Ewing sarcoma patients were presented at the 28 54th ASCO Annual Meeting in Chicago, IL. ORR was 18% and disease control rate was 57%. Partial response, stable disease &amp;gt;/= 4 months and SD for &amp;lt; 4 months, progressive disease was observed in 5, 6, 5 and 12 patients, respectively. PFS at 4 and 6 months was 42.9 and 21.4%, respectively. Transient myelosuppression was the main toxicity reported, and this was manageable with dose reductions and/or G-CSF use [&lt;ulink linkID="2039906" linkType="Reference"&gt;2039906&lt;/ulink&gt;]. At the same conference, further clinical data from small cell lung cancer patients were presented. Median response rates based on chemotherapy-free interval were 39.3%, 26.2%, 39.3%, 50.8%, 73.8%, 6.2, 4.1 and 11.8 for partial response, progressive disease, overall response rate (primary endpoint), clinical benefit, disease control rate, duration of response, progression-free survival and overall survival, respectively. Lurbinectedin was well-tolerated and there was no unexpected toxicity or drug-related deaths reported [&lt;ulink linkID="2039795" linkType="Reference"&gt;2039795&lt;/ulink&gt;]. In November 2018, patient enrollment was completed with a total of 100  patients [&lt;ulink linkID="2095592" linkType="Reference"&gt;2095592&lt;/ulink&gt;]. In March 2019, positive data from the lurbinectedin monotherapy trial for small cell lung cancer, were reported. The  trial met the primary endpoint  of ORR which was assesed by both investigator review and Independent Review Committee. The trial  enrolled 105 SCLC patients  in Europe and the US [&lt;ulink linkID="2133079" linkType="Reference"&gt;2133079&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2018, clinical data from open-label, phase I study (&lt;ulink linkID="207674" linkType="Protocol"&gt;NCT02210364&lt;/ulink&gt;) which evaluated the safety and pharmacokinetics of lurbinectedin (Zepsyre; PM-01183) in Japanese patients with advanced solid tumors were presented at the 54th ASCO Annual Meeting in Chicago, IL. Patients (n = 15) received three different dose levels of PM-01183 (1.5, 2.5 and 3.2 mg/m [2]), using a three+ three design. There no DLTs were reported in at dose 1.5 and 2.5 mg/m (2). At PM-01183 (3.2 mg/m [2]), two out of 4 patients had DLTs, which includes grade 3 neutropenia lasting &amp;gt; 7 days   and grade 4 neutropenia lasting &amp;gt; 3 days. At recommend dose (2.5 mg/ m[2]), neutropenia, ALT, AST , anorexia and nausea were the most common reported adverse events. At PM-01183 (1.5, 2.5 and 3.2 mg/m [2]) groups, mean Cmax values were 78.6, 129.4 and 90.4 microg/l; AUC was 273.8, 498.9 and 305.8 h. microg/l; clearance was 8.0, 9.9 and 17.4 l/h; t1/2 was 37.7, 51.2 and 42.2 h; volume of distribution was 219.4, 364.4 and 586.7 l; albumin was 3.8, 4 and 4 g/dl; alpha-1-acid glycoprotein was 109.7, 109.8 and 52 mg/dl and C-reactive proteins was 13.8, 12.2 and 0.9 mg/l, respectively [&lt;ulink linkID="2039891" linkType="Reference"&gt;2039891&lt;/ulink&gt;]. Further data were presented at the same conference. ORR was 57 and 60%, respectively, in overall patients and HR+ positive patients. In all (n = 28) and recommended dose (n = 15) groups, disease control rate (DCR: secondary endpoint; ORR + stable disease) was 86 and 80%, respectively; clinical benefit rate was 68 and 67%, respectively; duration of months was 6.8 and 6.8 months, respectively; and median progression free survival was 7.3 and 5.5 months, respectively [&lt;ulink linkID="2039988" linkType="Reference"&gt;2039988&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, an open-label, multi-center, phase I trial was initiated in  patients with solid tumors, in Japan [&lt;ulink linkID="1878529" linkType="Reference"&gt;1878529&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2016, clinical data from a study (&lt;ulink linkID="121097" linkType="Protocol"&gt;NCT01831089&lt;/ulink&gt;) were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Patients (n = 49) were received PM01183 (2.2 mg/m2 on day 1) + paclitaxel (80 mg/m2 on days 1 and 8, q3w) alone (arm-A) or without bevacizumab (arm-B) (15 mg/kg on day 1). Patients experienced DLT in cycle 1 were 2 and 3 in arm-A and B, respectively. There was no drug-drug interactions reported [&lt;ulink linkID="1805924" linkType="Reference"&gt;1805924&lt;/ulink&gt;]. In September 2017, further data from PM1183-A-007-13 study were presented at the ESMO 2017 Congress in Madrid, Spain. CR was achieved by one patient, PR was achieved by four patients, ORR was achieved by five patients, PD was observed in two patients, DCR was achieved by five patients, DOR was 2.3 months, PFS in patients with CTFI &amp;gt; 30 days and platinum-sensitive  patients was each 3.9 months [&lt;ulink linkID="1960731" linkType="Reference"&gt;1960731&lt;/ulink&gt;],[&lt;ulink linkID="1957802" linkType="Reference"&gt;1957802&lt;/ulink&gt;], [&lt;ulink linkID="1961482" linkType="Reference"&gt;1961482&lt;/ulink&gt;], [&lt;ulink linkID="1961385" linkType="Reference"&gt;1961385&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, an open-label, dose-ranging, uncontrolled, multicenter, phase I trial (&lt;ulink linkID="246414" linkType="Protocol"&gt;NCT02611024&lt;/ulink&gt;; PM1183-A-014-15) to evaluate the safety, efficacy and pharmacokinetics of lurbinectedin in combination with irinotecan in patients (expected n = 100) with advanced solid tumors was planned for August 2016 in the US. At that time, the trial was expected to complete in August 2019 [&lt;ulink linkID="1764678" linkType="Reference"&gt;1764678&lt;/ulink&gt;], [&lt;ulink linkID="1764502" linkType="Reference"&gt;1764502&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, results from a dose-escalating, phase I trial which evaluated the safety and efficacy of lurbinectedin in combination with cisplatin in the presence or absence of aprepitant, in patients (n = 29) with advanced solid tumors, were presented at the 2015 European Cancer Congress in Vienna, Austria. In a 3 + 3 design, patients were treated with a combination of cisplatin (at fixed dose of 60 mg/m2 in a 90-min infusion) followed by escalating PM-01183 (as 1 h infusion) both on day 1 q3w. Patients in arm 1 (n = 15) received po aprepitant on day 1 and days 2 to 3 (125 and 80 mg, respectively) prior to cisplatin and those in arm 2 (n = 14) received iv ondansetron (8 mg or equivalent) prior to cisplatin infusion. Mean Cmax (microg/l), AUC (h-microg/l), clearance, t1/2, Vss and volume of distribution base on terminal phase values for PM-01183 were 61.7, 433.5, 5.9, 43.6, 220.2 and 318.3 in arm A (PM-01183 at 1.1 mg/m2) and 79.9, 480.4, 9.9, 44.4, 255.4 and 499.1 in arm B (PM-01183 at 1.7 mg/m2), respectively. In aprepitant-treated patients, clearance of PM-01183 was reduced by 40% compared with those who did not receive aprepitant. Drug-drug interaction was not noted for cisplatin [&lt;ulink linkID="1698303" linkType="Reference"&gt;1698303&lt;/ulink&gt;]. In January 2017, further clinical data were presented at ECCO 2017 in Amsterdam, the Netherlands. The recommended dose (RD) in Arm A  was PM-01183 (1.1 mg/m2) + cisplatin (60 mg/m2) and in Arm B was PM-01183 (1.4 mg/m2) + cisplatin (60 mg/m2) (primary endpoint). Partial response, stable disease and partial disease was observed in 2, 10 and 5 patients in Arm A (n = 17), respectively; and 2, 13 and 6 patients in Arm B (n = 21), respectively. At  RD, in Arm A, adverse events (AEs) like anemia, neutropenia, thrombocytopenia, creatinine, ALT, AST, nausea, vomiting, constipation, asthenia, anorexia, paraesthesia and hearing impairment were observed; while in Arm B, AEs like anemia, neutropenia, thrombocytopenia, creatinine, ALT, AST, nausea, vomiting, constipation, asthenia, anorexia, diarrhea and tinnitus were observed   [&lt;ulink linkID="1895877" linkType="Reference"&gt;1895877&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, clinical data were presented at the 26th EORTC-NCI-AACR Symposium in Barcelona, Spain. The mean clearance, AUC, Cmax and t1/2 at the recommended  dose for  PM-01183  were 18.1 l/h, 318 h.microg/l, 90.5 microg/l and 30.5 h, respectively. A statistically significant relationship was found between clearance and body surface area [&lt;ulink linkID="1612576" linkType="Reference"&gt;1612576&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2011, an open-label, multicenter, interventional, single-group assigned, phase I trial (&lt;ulink linkID="79643" linkType="Protocol"&gt;NCT01405391&lt;/ulink&gt;, PM1183-A-005-11) in non-colorectal cancer patients (n = 42) had been initiated to assess the safety and efficacy of lurbinectedin. At that time, the study was to be completed in November 2013 [&lt;ulink linkID="1252478" linkType="Reference"&gt;1252478&lt;/ulink&gt;], [&lt;ulink linkID="1206636" linkType="Reference"&gt;1206636&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, an open-label, phase I, dose-escalating study of lurbinectedin (&lt;ulink linkID="51068" linkType="Protocol"&gt;NCT00877474&lt;/ulink&gt;; PM1183-A-001-08) of began in patients with advanced solid tumors (expected n = 35). The primary endpoint was to identify dose-limiting toxicities, maximum-tolerated dose and recommended dose. The secondary endpoint was to determine pharmacokinetics, antitumor activity and safety, as well as pharmacogenomics in tumor samples and peripheral white blood cells  at the recommended dose [&lt;ulink linkID="1027145" linkType="Reference"&gt;1027145&lt;/ulink&gt;]. In November 2010, data from this study were presented at the 22nd EORTC-NCI-AACR Symposium in Berlin, Germany. Full accrual was completed in September 2010. Patients received dose levels from 0.02 to 5.0 mg/m2. The recommended dose for phase II was determined as 4 mg/m2 administered as a 1-h iv infusion once every 3 weeks. At this dose, 1 of the 15 patients treated thus far experienced a DLT of grade 4 thrombocytopenia, and grade 4 neutropenia was observed in 40% of this cohort, although it showed a short duration and was clinically manageable. The MTD of 5 mg/m2 in 3 patients resulted in 2 patients each experiencing grade 4 transaminase elevations and grade 4 neutropenia. Good dose proportional pharmacokinetic data were seen. One pancreatic tumor patient showed a partial response after 3 cycles of treatment [&lt;ulink linkID="1145911" linkType="Reference"&gt;1145911&lt;/ulink&gt;], [&lt;ulink linkID="1149246" linkType="Reference"&gt;1149246&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hematological cancer&lt;/subtitle&gt;In May 2011, an open-label dose-escalation phase I trial (&lt;ulink linkID="75489" linkType="Protocol"&gt;NCT01314599&lt;/ulink&gt;; PM1183-A-002-10) began in patients with advanced acute leukemia. The primary outcome measure was MTD and recommended dose in patients with acute leukemia. Antileukemic activity, pharmacokinetics and pharmacogenomics were to be secondary endpoints. The trial was designed to enroll 30 patients and complete in September 2013 [&lt;ulink linkID="1205863" linkType="Reference"&gt;1205863&lt;/ulink&gt;], [&lt;ulink linkID="1281956" linkType="Reference"&gt;1281956&lt;/ulink&gt;]. In November 2012, recruitment of patients with acute lymphoblastic leukemia was ongoing [&lt;ulink linkID="1343928" linkType="Reference"&gt;1343928&lt;/ulink&gt;]. In July 2015, trial was completed [&lt;ulink linkID="1205863" linkType="Reference"&gt;1205863&lt;/ulink&gt;]. In June 2017, clinical data were presented at the 53rd ASCO meeting in Chicago, IL. A total of three patients had DLTs, which were rhabdomyolysis (up to grade 4), hyperbilirubinemia (grade 3), and oral herpes (grade 3). All DLTs occurred in the 6 and 7 mg cohorts. Febrile neutropenia/infections (n = 3), gastrointestinal (n = 6) and pulmonary (n = 2) toxicity, hyperhidrosis (n = 1), and QT prolongation (n = 1) were the reported adverse events (AEs). A patient had partial response, two patients had morphologic leukemia-free survival, and most (n = 30) were discontinued due to progressive disease [&lt;ulink linkID="1940356" linkType="Reference"&gt;1940356&lt;/ulink&gt;], [&lt;ulink linkID="1937328" linkType="Reference"&gt;1937328&lt;/ulink&gt;]. In December 2018, further data were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. Lurbinectedin on day 1 and 8 (initial cohort) was considered unfeasible and inadequate for leukemia treatment and patients received lurbinectedin on days 1 to 3 q21d at 2, 3, 1 and 1.5 mg (subsequent cohort). The DLTs reported were hyperbilirubinemia (n = 1) with 7 mg dose (day 1, 8), oral herpes (n = 1) with 7 mg dose (day 1, 8) and rhabdomyolysis (n = 1) with 7 mg dose (day 1, 8). Among 24 efficacy evaluable patients, the median PFS was 0.7 (day 1, 8) and 0.5 months (day 1 to 3). Among 42 patients, 33 had reduction in blasts; 23 with &amp;gt; 50% reduction in bone marrow or peripheral blood blasts, and 5 with &amp;gt; 50% reduction in both bone marrow or peripheral blood blasts [&lt;ulink linkID="2098582" linkType="Reference"&gt;2098582&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Small-cell lung cancer&lt;/subtitle&gt;In January 2015, the company planned to initiate a head-to-head, phase III trial in combination with doxorubicin in patients with relapsed small-cell lung cancer (SCLC), which would compare the combination as second line therapy against &lt;ulink linkID="4577" linkType="Drug"&gt;topotecan&lt;/ulink&gt;. At that time, data were expected to be presented at a prominent international cancer meeting that year [&lt;ulink linkID="1626214" linkType="Reference"&gt;1626214&lt;/ulink&gt;]. In September 2015, a pivotal, randomized, open-label, parallel assignment, efficacy, phase III study (&lt;ulink linkID="241930" linkType="Protocol"&gt;NCT02566993&lt;/ulink&gt;; PM1183-C-003-14; ATLANTIS) was planned to be initiated in patients (expected n = 600) with SCLC who failed one prior platinum-containing line. The trial would test lurbinectedin plus doxorubicin compared to topotecan or CAV (cyclophosphamide, adriamycin, vincristine). At that time, the study was expected to be completed in November 2018 [&lt;ulink linkID="1701365" linkType="Reference"&gt;1701365&lt;/ulink&gt;]. In February 2016, the trial was expected to begin in 2016 [&lt;ulink linkID="1739173" linkType="Reference"&gt;1739173&lt;/ulink&gt;]. In July 2016, the multicenter, controlled trial began [&lt;ulink linkID="1784693" linkType="Reference"&gt;1784693&lt;/ulink&gt;]. In August 2017,  completion of enrollment was expected  around first half of 2018 [&lt;ulink linkID="1957802" linkType="Reference"&gt;1957802&lt;/ulink&gt;]. In October 2017, it was presented at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan that the enrollment started in September 2016 (target n = approximately 600), and was expected to be completed at the beginning of 2018. Patients from in 154 sites in USA, Canada, LATAM and Europe would be randomized (1:1) to receive doxorubicin 50 mg/m2 + lurbinectedin 3-5 mg (flat dose day 1 q3w) and continue with lurbinectedin 7 mg flat dose after doxorubicin cumulative dose of 450 mg/m2 in cohort 1; and doxorubicin 40 mg/m2 + lurbinectedin 2 mg/m2 (day 1 q3w) and continue with lurbinectedin 4 mg/m2 after doxorubicin cumulative dose of 450 mg/m2 in cohort 2. The primary endpoint analysis was 484 events of progression-free survival. Two ad-hoc interim safety analyses were being conducted at the time of presentation in the first 50 and the first 100 patients who randomized and treated with two cycles [&lt;ulink linkID="1971953" linkType="Reference"&gt;1971953&lt;/ulink&gt;]. In November 2017, based on the positive safety data obtained with the first 150 patients treated in the trial, the IDMC recommended to continue the trial without any changes [&lt;ulink linkID="1982417" linkType="Reference"&gt;1982417&lt;/ulink&gt;]. In February 2018, patient enrollment was expected to complete by mid-2018 [&lt;ulink linkID="2006767" linkType="Reference"&gt;2006767&lt;/ulink&gt;]. In May 2018, the IDMC recommended  continuation of the  trial without any amendment, following the  analysis of the safety data obtained from more than 500 patients  [&lt;ulink linkID="2038224" linkType="Reference"&gt;2038224&lt;/ulink&gt;]. In June 2018, PharmaMar filed a protocol amendment with the FDA and other competent authorities for the phase III ATLANTIS trial to change the primary endpoint from progression free survival (PFS) to overall survival (OS) based on recent receipt of OS data from a phase II trial. At that time, enrollment was expected to complete in third quarter of 2018 and  top line data were expected  in second half of 2019 [&lt;ulink linkID="2043770" linkType="Reference"&gt;2043770&lt;/ulink&gt;]. In June 2018, it was reported that the trial was about to finalize recruitment in July 2018. Single agent lurbinectedin treatment in SCLC gave an overall survival benefit of 11.8 months [&lt;ulink linkID="2048984" linkType="Reference"&gt;2048984&lt;/ulink&gt;]. In July 2018, the study reached its recruitment objective of 600 patients from 160 centers in 20 countries. At that time, results were expected in the end of 2019 [&lt;ulink linkID="2075394" linkType="Reference"&gt;2075394&lt;/ulink&gt;]. In October 2018,  the IDMC recommended  continuation of the  trial without any changes [&lt;ulink linkID="2087907" linkType="Reference"&gt;2087907&lt;/ulink&gt;]. By December 2018, recruitment of  105 patients with relapsed SCLC was completed [&lt;ulink linkID="2124901" linkType="Reference"&gt;2124901&lt;/ulink&gt;]. In June 2019, results were expected in 2020 [&lt;ulink linkID="2168751" linkType="Reference"&gt;2168751&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination trials&lt;/subtitle&gt;In February 2017, a phase III trial was initiated in patients with SCLC to assess lurbinectedin in combination with doxorubicin. Patient recruitment was expected to conclude in 2018 [&lt;ulink linkID="1903469" linkType="Reference"&gt;1903469&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  September 2015, results from a preliminary analysis of a study that examined PM-01183 in combination with paclitaxel in patients with advanced solid tumors (n = 54) were presented at the 2015 European Cancer Congress in Vienna, Austria. Patients were treated with paclitaxel weekly until week 18 and paclitaxel was stopped at week 18 and patients continued on lurbinectedin alone as long as clinical was maintained. Combination of PM-01183 on day 1 and paclitaxel on days 1 and 8 q3w tolerated well with no unexpected toxicities. Myelosuppression, particularly neutropenia, was the DLT observed at the recommended dose. Overall response rate according to Response Evaluation Criteria In Solid Tumors was 38% (n = 45) [&lt;ulink linkID="1698220" linkType="Reference"&gt;1698220&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, an open label, multicenter, single group phase I trial (&lt;ulink linkID="159146" linkType="Protocol"&gt;NCT01970540&lt;/ulink&gt;, PM1183-A-003-10 ) in combination with doxorubicin was initiated in patients (expected n = 73) with selected advanced solid tumors including endometrial adenocarcinomas, neuroendocrine tumors, bladder, gastric, breast, soft-tissue sarcomas  and SCLC. At that time, the trial was expected to be completed in June 2015 [&lt;ulink linkID="1608168" linkType="Reference"&gt;1608168&lt;/ulink&gt;], [&lt;ulink linkID="1606714" linkType="Reference"&gt;1606714&lt;/ulink&gt;], [&lt;ulink linkID="1626214" linkType="Reference"&gt;1626214&lt;/ulink&gt;]; Later that month, phase Ib data from studies of lurbinectedin in combination with doxorubicin were presented at the15th World Conference on Lung Cancer (WCLC) in Sydney, Australia. Of the 43 patients enrolled in the study, 13 had small cell lung cancer (SCLC). Of the SCLC patients, 12 were evaluable and an overall response rate of 42% was seen. However, all responses were seen in patients who had only received one prior line of therapy. The second-line overall response rate was 71%. Progressive disease, partial response and stable disease was seen in 50, 42 and 8% of patients, respectively. The recommended dose was established as 4-mg lurbinectedin plus 50-mg/m2 doxorubicin on day 1 q3wk, with efficacy seen in chemosensitive and chemorefractory patients. The most frequent adverse event was reversible severe myelosuppression. There were no grade 5 events and no signs of increased cardiotoxicity [&lt;ulink linkID="1492959" linkType="Reference"&gt;1492959&lt;/ulink&gt;], [&lt;ulink linkID="1491290" linkType="Reference"&gt;1491290&lt;/ulink&gt;]. By January 2015, further results were reported. Data demonstrated, that the treatment was well-tolerated, and patients showed a marked objective tumor responses and were able to receive several cycles of treatment [&lt;ulink linkID="1626214" linkType="Reference"&gt;1626214&lt;/ulink&gt;]. In June 2015, data from the trial were presented at the 51st ASCO meeting in Chicago, IL. During treatment, partial response, complete response, stable disease, progressive disease, and overall response rate were 57, 10, 14, 19, and 67%, respectively. Data demonstrated that treatment with lurbinectedin + doxorubicin was feasible at the targeted dose intensity [&lt;ulink linkID="1663862" linkType="Reference"&gt;1663862&lt;/ulink&gt;], [&lt;ulink linkID="1666381" linkType="Reference"&gt;1666381&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 53rd ASCO meeting in Chicago, IL.  The duration of response and progression free survival was 19.5 and 7.8 months (cohort-A), 6.8 and 7.7 months (cohort-B), 6.1 and 1.9 months (lurbinectedin + paclitaxel), 6.8 and 2.6 months (lurbinectedin), respectively. The adverse events reported in all groups were anemia, neutropenia, febrile neutropenia, thrombopenia, ALT, AST, fatigue, nausea, vomiting, diarrhea, constipation and sepsis [&lt;ulink linkID="1932174" linkType="Reference"&gt;1932174&lt;/ulink&gt;], [&lt;ulink linkID="1937328" linkType="Reference"&gt;1937328&lt;/ulink&gt;]. In September 2017, further data were presented at the ESMO 2017 Congress in Madrid, Spain. In cohort A and B, stable disease (SD) was observed in 3 and 9 patients, respectively; progressive disease (PD) was observed in 4 and 8 patients, respectively; disease control rate (DCR) was achieved by 17 and 19 patients, respectively; duration of response (DOR) was 4.5 and 5.2 months, respectively; progression-free survival (PFS) in patients with chemotherapy free interval (CTFI) &amp;gt; 30 days was 4.7 and 5.3 months, respectively; and in platinum-sensitive  patients was 5.8 and 6.2 months, respectively [&lt;ulink linkID="1960731" linkType="Reference"&gt;1960731&lt;/ulink&gt;], ,[&lt;ulink linkID="1957802" linkType="Reference"&gt;1957802&lt;/ulink&gt;], [&lt;ulink linkID="1961482" linkType="Reference"&gt;1961482&lt;/ulink&gt;], [&lt;ulink linkID="1961385" linkType="Reference"&gt;1961385&lt;/ulink&gt;]. In October 2017, similar and final data from the phase I/II trial were presented at the International Association for the Study of Lung Cancer, at 18th WCLC in Yokohama, Japan. Data demonstrated that the progression free survival increased up to 6.2 months in patients treated with PM-1183 in combination with doxorubicin in platinum-sensitive patients; and with topotecan, the survival rate was ranged from 3.25 to 4.3 months [&lt;ulink linkID="1972135" linkType="Reference"&gt;1972135&lt;/ulink&gt;], [&lt;ulink linkID="1972063" linkType="Reference"&gt;1972063&lt;/ulink&gt;]. In September 2018, data from cohort B of phase I/II trial were presented at the International Association for the Study of Lung Cancer, at WCLC in Toronto, Canada. Data demonstrated that the overall survival increased upto 10.2 months in patients treated with lurbinectedin in combination with doxorubicin in platinum-sensitive patients reaching 11.5 months [&lt;ulink linkID="2075394" linkType="Reference"&gt;2075394&lt;/ulink&gt;]. Further clinical data were presented at the same conference. The overall progression free survival was 3.4 months and in chemotherapy free interval resistant and sensitive patients, the progression free survival was 1.5 and 5.7 months, respectively. Overall survival was found to be 7.9, 4.9 and 11.5 months in overall population, chemotherapy free interval resistant and sensitive population, respectively [&lt;ulink linkID="2080771" linkType="Reference"&gt;2080771&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, a phase Ib, prospective, open-label, dose-escalating trial began in Spain and Belgium in patients with unresectable metastatic breast cancer, pancreatic cancer and metastatic colon cancer. The trial was to assess lurbinectedin plus capecitabine. The primary endpoint was to determine the recommended dose of lurbinectedin in combination with capecitabine in patients with advanced solid tumors [&lt;ulink linkID="1427626" linkType="Reference"&gt;1427626&lt;/ulink&gt;]. In September 2014, data were presented from 55 patients at the 39th European Society for Medical Oncology congress in Madrid, Spain. The recommended dose was found to be 2 mg flat-dose of lurbinectedin on days 1 and 8 + 1650 mg/m2 of capecitabine bid on days 1 to 14 q3w. In colorectal cancer, pancreatic cancer and metastatic breast cancer (MBC) patient groups, 29, 0 and 33% of patients achieved partial response, respectively, and 43, 75 and 0% of patients had stable disease for 4 months or longer, respectively [&lt;ulink linkID="1597517" linkType="Reference"&gt;1597517&lt;/ulink&gt;]. In October 2016, further clinical data were presented at the ESMO 2016 Congress in Copenhagen, Denmark. At the RD, DLT was observed in 3 of 35 evaluable patients, all three were lack of compliance due to myelosuppression. At the RD, grade 4 neutropenia or thrombocytopenia was observed in 14 and 3% of patients, respectively; while none had febrile neutropenia or any grade 4 non-hematological toxicity; grade 3 fatigue or hypertension was observed once each.  A total of 12 of 25 MBC patients responded for a 48% response rate including 3 of 8 with triple negative tumors. In MBC patients, median time-to-progression was 26+ weeks, 10 patients were ongoing as May 2016. The pharmacokinetics of PM-01183 was unaffected by capecitabine administration [&lt;ulink linkID="1805996" linkType="Reference"&gt;1805996&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, phase I development for the drug in combination with other chemotherapies in haematological tumors were ongoing [&lt;ulink linkID="1416459" linkType="Reference"&gt;1416459&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2011, two phase I studies which would evaluate the drug in combination with gemcitabine and doxorubicin had been ongoing [&lt;ulink linkID="1252455" linkType="Reference"&gt;1252455&lt;/ulink&gt;]. In October 2012, data were presented from an ongoing phase I study (3 + 3 design) in  combination with  gemcitabine in selected solid tumor patients  (n = 34) at the 37th European Society for Medical Oncology Congress in Vienna, Austria. The recommended dose was found to be 3.5 mg PM-01183 plus 800 mg/m2 gemcitabine. The mean Cmax, AUC, clearance and half life values of lurbinectedin at the recommended dose were 78 microg/l, 473 h.microg/ml, 10.4 l/h and 53.6 h, respectively [&lt;ulink linkID="1325264" linkType="Reference"&gt;1325264&lt;/ulink&gt;]. In October 2013, further data were presented at the15th WCLC in Sydney, Australia. Data from NSCLC patients showed an overall response rate of 31%, with a complete and partial response rate of 6 and 25%, respectively, and a stable and progressive disease rate of 44 and 25%, respectively. Efficacy was seen in several types of pretreated patients at all dose levels tested, but two toxic deaths occurred at higher doses. Recommended dose of 3-mg lurbinectedin in combination with 800-mg/m2 gemcitabine was given. A Kaplan-Meier estimate showed median progression-free survival of 3.9 months with a progression-free survival rate at 6 months of 30% [&lt;ulink linkID="1492959" linkType="Reference"&gt;1492959&lt;/ulink&gt;], [&lt;ulink linkID="1491192" linkType="Reference"&gt;1491192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In April 2014, clinical data were presented at the 105th AACR meeting in San Diego, CA. Ewing sarcoma patients treated with PM-01183 exhibited 15 times higher serum concentrations than that required to EWS/FLI1 inhibition. At that time, translation of PM-01183 to phase I/II trial in pediatric solid tumors/Ewing sarcoma patients were planned and mechanism of action of EWS/FLI1 suppression and optimized schedule of administration of PM-01183 + irinotecan findings were planned [&lt;ulink linkID="1539212" linkType="Reference"&gt;1539212&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2017, in vitro data were presented at the 108th AACR Annual Meeting in Washington DC. Lurbinectedin reversed platinum dependent IRF1 overexpression and nuclear localization, and partially responsible for resistance to platinum drugs in ovarian cancer. In A2780 cells, lurbinectedin  and cisplatin combinations showed clear synergism [&lt;ulink linkID="1914575" linkType="Reference"&gt;1914575&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2016, preclinical data were presented at the ESMO 2016 Congress in Copenhagen, Denmark. In a panel of gBRCA patient-derived xenograft (PDX) models, treatment with PM-01183 (0.18 mg/kg, iv) showed anti-tumor activity (partial response, complete response or stabilization) in 75% of the PDX models [&lt;ulink linkID="1805914" linkType="Reference"&gt;1805914&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. In Ewing sarcoma cell lines, trabectedin and PM-01183 treatment resulted in the accumulation of EWS/FLI1 in the nucleolus, which was associated with a loss of binding at target sequences and reverse in the expression of EWS/FLI1 gene signature. In Ewing sarcoma xenografts, trabectedin + PM-01183 combination treatment resulted in the tumor to be replaced by benign adipocytes [&lt;ulink linkID="1755157" linkType="Reference"&gt;1755157&lt;/ulink&gt;]. Additional preclinical data were presented at the same conference. In human monocytes, lurbinectedin and trabectedin produced dose-dependent apoptosis, activated caspase-8 and had comparable cytotoxic potential. In fibrosarcoma-bearing mice, lurbinectedin and trabectedin treatment produced selective decreases in the number of total monocytes (CD11b+CD115+), Ly6C(high) monocytes, total macrophages (CD11b+ F4/80+) and Ly6C(high) macrophages and significantly reduced tumors in macrophages and vessels [&lt;ulink linkID="1753980" linkType="Reference"&gt;1753980&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. In a panel of various human cancer cell lines, lurbinectedin bind to DNA and had a strong antiproliferative effect. Lurbinectedin showed preferential binding to GC-rich regions that surround the prompter of genes. In A549 lung cancer cells, lurbinectedin inhibited the transcription and triggered the degradation of Rpb1, which was the catalytic subunit of Pol II [&lt;ulink linkID="1754029" linkType="Reference"&gt;1754029&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 106th AACR meeting in Philadelphia, PA. In both H526 and H82 SCLC xenograft models, PM-1183 (0.18, 0.135, 0.09 and 0.045 mg/kg, iv) qw treatment showed significant reduction of tumor growth when compared with placebo. PM-1183 in combination with doxorubicin (2, 4, 6 and 8 mg/kg iv) showed significant tumor growth reduction with synergistic or additive effect when compared with doxorubicin and PM-1183 alone.[&lt;ulink linkID="1649492" linkType="Reference"&gt;1649492&lt;/ulink&gt;]. Further preclinical data were also presented at the same conference showing that  in various cancer cell lines, PM-1183 plus AZD-2281 or BMN-673 combination synergistically reduced the cell growth compared with monotherapies [&lt;ulink linkID="1649482" linkType="Reference"&gt;1649482&lt;/ulink&gt;], [&lt;ulink linkID="1654071" linkType="Reference"&gt;1654071&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, preclinical data were presented at the 26th EORTC-NCI-AACR Symposium in Barcelona, Spain. In olaparib-resistant tumor models, PDX196 and PDX127, PM-01183 (0.18 mg/kg/week, iv) showed antitumor activity [&lt;ulink linkID="1612138" linkType="Reference"&gt;1612138&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  November 2014, preclinical data were presented at the 26th EORTC-NCI-AACR Symposium in Barcelona, Spain. Lurbinectedin (30 nM) induces time- and concentration-dependent degradation specifically against RNA polymerase II in tumor cells. RNA polymerase II degradation by lurbinectedin was dependent on active transcription, ubiquitination and the proteasome machinery [&lt;ulink linkID="1612701" linkType="Reference"&gt;1612701&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2014, preclinical data were presented at the 105th AACR meeting in San Diego, CA. PM-01183 (5, 2.5 and 1.25 nM) significantly suppressed the EWS/FLI1 gene signature in a dose-dependent manner when compared with the trabectedin. In TC32 and TC71 cell lines (Ewing sarcoma), trabectedin mediated suppression of EWS/FLI1 target proteins was maintained by PM-01183.  Comparable synergy was observed between PM-01183 and &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; as trabectedin in TC32 cells. Increased tumor necrosis was observed with PM-01183 (0.18 mg/kg iv) and irinotecan (5 mg/kg iv) combination. In vivo, PM-01183 + irinotecan significantly suppressed the EWS/FLI1 activity [&lt;ulink linkID="1539212" linkType="Reference"&gt;1539212&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were presented at the AACR Annual Meeting in Washington, DC. In HCT-116 (colon carcinoma) and A549 (lung carcinoma) cells, lurbinectedin (10 to 90 nM) dose- and time-dependently induced rapid degradation of RNA polymerase II. In A549 (lung carcinoma) cells, lurbinectedin (30 nM)-induced degradative pathway occurred specifically targeting RNA polymerase II. In A549 (lung carcinoma) cells, DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole; 25 microM), a transcription inhibitor, but not AcD (1 microg/ml) or alpha-amanitin (10, 20 and 50 microg/ml) protects the degradation of RNA polymerase II induced by lurbinectedin (30 nM) [&lt;ulink linkID="1402212" linkType="Reference"&gt;1402212&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, data were presented at the 24th EORTC-NCI-AACR symposium in Dublin, Ireland. In athymic nu/nu mice xenografted with pancreatic (SW1990), ovarian (A2780) and NSCLC (H460) tumors, PM-01183 at 0.18 mg/kg induced double stranded breaks and apoptosis. PM-01183 demonstrated significant in vivo tumor effect. In female athymic nu/nu mice xenografted with pancreatic (SW1990), ovarian (A2780) and NSCLC (H460) tumors, PM-01183 (0.180 mg/kg) + gemcitabine (180 mg/kg) increased the level of tumor apoptosis compared to PM-01183 and gemcitabine alone, in agreement with the in vivo synergistic activity observed after combination treatment. In PM-01183 + gemcitabine treatment complete remission (CR) was observed in Panc-026 (9 CR/10 mice), Panc-265 (1 CR/7 mice), Panc-354 (4 CR/6 mice) and JH-024 (5 CR/10 mice).  In M5076 model, marginal activity against primary tumor with best therapeutic cure (T/C) of 73.4% and positive antimetastatic activity by reducing the number of liver metastasis was showed by PM-01183 (median = 0.5). PM-01183 demonstrated potent antitumor activity with best T/C of 15% and positive antimetastatic activity by reducing the number of liver metastasis (median = 1.5) in MNMCA1 model. In intraperitoneal model, PM-01183 effectively prolonged survival of HOC8 bearing mice with ILS% of 140. Of the nine mice treated with PM-01183, eight were alive and were considered cured. PM-01183 sc was inactive against MNB-PTXI xenograft but was active in HOC 18 xenograft (T/C of 12.8%)   [&lt;ulink linkID="1336030" linkType="Reference"&gt;1336030&lt;/ulink&gt;], [&lt;ulink linkID="1336027" linkType="Reference"&gt;1336027&lt;/ulink&gt;], [&lt;ulink linkID="1336032" linkType="Reference"&gt;1336032&lt;/ulink&gt;], [&lt;ulink linkID="1336034" linkType="Reference"&gt;1336034&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2012, preclinical data were presented at the 103rd AACR meeting in Chicago, IL. In vivo, PM-01183 (0.18 mg/kg, iv) demonstrated antitumor activity in MBA-MD-231 tumor mice models. Sustained PM-01183 levels were found in both breast and pancreatic xenograft models, at the MTD level. High PM-01183 levels were observed in both breast and pancreatic models [&lt;ulink linkID="1275550" linkType="Reference"&gt;1275550&lt;/ulink&gt;], [&lt;ulink linkID="1277749" linkType="Reference"&gt;1277749&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, preclinical data were presented at the 103rd AACR meeting in Chicago, IL. PM-01183 demonstrated strong antitumor activity in OVAX1 (patient-derived cisplatin-sensitive cells) and OVAX1R serous epithelial ovarian orthotopic tumor models. In ovarian (A2780) xenografted tumors, a strong synergy resulted from the combination of PM-01183 and &lt;ulink linkID="51933" linkType="Drug"&gt;cisplatin&lt;/ulink&gt; [&lt;ulink linkID="1275547" linkType="Reference"&gt;1275547&lt;/ulink&gt;], [&lt;ulink linkID="1277749" linkType="Reference"&gt;1277749&lt;/ulink&gt;]. In July 2012, these data were presented at the 22nd EACR Congress in Barcelona, Spain [&lt;ulink linkID="1307274" linkType="Reference"&gt;1307274&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, preclinical data were presented at the 103rd AACR meeting in Chicago, IL. PM-01183 induced NP9Luc tumor reductions in  bioluminescence performed in athymic nude female mice. Statistically, tumor sizes were significantly smaller than either placebo or gemcitabine-treated groups. Mean survival time was significantly high in PM-01183 (n = 12, 24.5 days) treated group compared to placebo-(n =12; 11.9 days) or &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt;-treated groups (n =12; 16.9 days). PM-01183 in combination with gemcitabine synergistically induced antitumor effects in mice bearing NP9Luc xenografted tumors [&lt;ulink linkID="1275545" linkType="Reference"&gt;1275545&lt;/ulink&gt;], [&lt;ulink linkID="1277749" linkType="Reference"&gt;1277749&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2010, preclinical data were presented at the 22nd EORTC-NCI-AACR Symposium in Berlin, Germany, showing that lurbinectedin demonstrated  cytotoxic activity against platinum-resistant cells, inhibited the repair of ultraviolet-induced DNA lesions and acted synergistically cisplatin in cisplatin-sensitive and cisplatin-resistant ovarian cancer cells [&lt;ulink linkID="1146120" linkType="Reference"&gt;1146120&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2009, preclinical data on lurbinectedin were presented at the 100th AACR Meeting in Denver, CO. In a number of cell lines increased potency was shown. In the M5076 sarcoma model tumor growth inhibition was observed, including a significant decrease in the number of liver metastasis compared to placebo. In the MNMCA model, good antitumor activity was demonstrated following lurbinectedin treatment. Studies in human ovarian cancer and human sarcoma xenografts were being carried out [&lt;ulink linkID="996088" linkType="Reference"&gt;996088&lt;/ulink&gt;], [&lt;ulink linkID="1001789" linkType="Reference"&gt;1001789&lt;/ulink&gt;]. Lurbinectedin exhibited the strongest activity against  mutant/null p53 human tumor cell lines and was shown to bind to naked DNA and generate double-strand breaks, which led to the induction of caspase-dependent apoptotic cell death. A statistically significant  antitumor effect in breast, kidney and ovary cancer xenografts was observed [&lt;ulink linkID="997978" linkType="Reference"&gt;997978&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2017-10-17T00:00:00.000Z</StatusDate><Source id="1971953" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2016-10-18T00:00:00.000Z</StatusDate><Source id="1864303" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2017-10-17T00:00:00.000Z</StatusDate><Source id="1971953" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2015-05-05T00:00:00.000Z</StatusDate><Source id="1653269" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2017-10-17T00:00:00.000Z</StatusDate><Source id="1971953" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2017-10-17T00:00:00.000Z</StatusDate><Source id="1971953" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2016-08-02T00:00:00.000Z</StatusDate><Source id="1784693" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3737">Germ cell and embryonic cancer</Indication><StatusDate>2015-07-07T00:00:00.000Z</StatusDate><Source id="1676326" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2015-07-07T00:00:00.000Z</StatusDate><Source id="1676326" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1515">Biliary tumor</Indication><StatusDate>2015-07-07T00:00:00.000Z</StatusDate><Source id="1676326" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2975">Ewing sarcoma</Indication><StatusDate>2015-09-17T00:00:00.000Z</StatusDate><Source id="1695732" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2975">Ewing sarcoma</Indication><StatusDate>2015-07-07T00:00:00.000Z</StatusDate><Source id="1676326" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate>2011-06-08T00:00:00.000Z</StatusDate><Source id="1205988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication><StatusDate>2017-09-28T00:00:00.000Z</StatusDate><Source id="2105352" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2011-10-24T00:00:00.000Z</StatusDate><Source id="1252455" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-09-17T00:00:00.000Z</StatusDate><Source id="1695732" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate>2015-07-07T00:00:00.000Z</StatusDate><Source id="1676326" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2015-09-17T00:00:00.000Z</StatusDate><Source id="1695732" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate>2015-09-17T00:00:00.000Z</StatusDate><Source id="1695732" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication><StatusDate>2017-09-28T00:00:00.000Z</StatusDate><Source id="2105352" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2011-10-24T00:00:00.000Z</StatusDate><Source id="1281956" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-06-21T00:00:00.000Z</StatusDate><Source id="1309233" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate>2011-06-08T00:00:00.000Z</StatusDate><Source id="1205988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-06-21T00:00:00.000Z</StatusDate><Source id="1309233" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3737">Germ cell and embryonic cancer</Indication><StatusDate>2015-09-17T00:00:00.000Z</StatusDate><Source id="1695732" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1515">Biliary tumor</Indication><StatusDate>2015-09-17T00:00:00.000Z</StatusDate><Source id="1695732" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2016-11-28T00:00:00.000Z</StatusDate><Source id="1878529" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate>2013-05-20T00:00:00.000Z</StatusDate><Source id="1427626" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3672">Metastatic colon cancer</Indication><StatusDate>2013-05-20T00:00:00.000Z</StatusDate><Source id="1427626" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3672">Metastatic colon cancer</Indication><StatusDate>2013-05-20T00:00:00.000Z</StatusDate><Source id="1427626" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1727">Acute leukemia</Indication><StatusDate>2011-05-18T00:00:00.000Z</StatusDate><Source id="1205863" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate>2013-05-20T00:00:00.000Z</StatusDate><Source id="1427626" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2017-05-18T00:00:00.000Z</StatusDate><Source id="1928583" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2017-05-18T00:00:00.000Z</StatusDate><Source id="1928583" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2017-05-18T00:00:00.000Z</StatusDate><Source id="1928583" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-05-18T00:00:00.000Z</StatusDate><Source id="1928583" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2019-04-26T00:00:00.000Z</StatusDate><Source id="2146288" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2017-05-18T00:00:00.000Z</StatusDate><Source id="1928583" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-05-18T00:00:00.000Z</StatusDate><Source id="1928583" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14987">Boryung Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2017-11-07T00:00:00.000Z</StatusDate><Source id="1978834" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2017-05-18T00:00:00.000Z</StatusDate><Source id="1928583" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-05-18T00:00:00.000Z</StatusDate><Source id="1928583" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14987">Boryung Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2017-11-07T00:00:00.000Z</StatusDate><Source id="1978834" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2017-05-18T00:00:00.000Z</StatusDate><Source id="1928583" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14987">Boryung Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-11-07T00:00:00.000Z</StatusDate><Source id="1978834" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2018-06-26T00:00:00.000Z</StatusDate><Source id="1887758" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2018-06-26T00:00:00.000Z</StatusDate><Source id="1887758" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2018-06-26T00:00:00.000Z</StatusDate><Source id="2048984" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2017-05-12T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-02-02T00:00:00.000Z</StatusDate><Source id="1261193" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-03-31T00:00:00.000Z</StatusDate><Source id="1027145" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2015-01-13T00:00:00.000Z</StatusDate><Source id="1626214" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2015-06-29T00:00:00.000Z</StatusDate><Source id="1673894" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2016-12-22T00:00:00.000Z</StatusDate><Source id="1887758" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2016-12-22T00:00:00.000Z</StatusDate><Source id="1887758" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2016-12-22T00:00:00.000Z</StatusDate><Source id="1887758" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2015-07-07T00:00:00.000Z</StatusDate><Source id="1676326" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2015-07-07T00:00:00.000Z</StatusDate><Source id="1676326" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2015-09-17T00:00:00.000Z</StatusDate><Source id="1695732" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate>2012-08-29T00:00:00.000Z</StatusDate><Source id="1319184" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2014-10-12T00:00:00.000Z</StatusDate><Source id="1487633" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2013-05-20T00:00:00.000Z</StatusDate><Source id="1427626" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-03-31T00:00:00.000Z</StatusDate><Source id="1027145" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2975">Ewing sarcoma</Indication><StatusDate>2014-04-08T00:00:00.000Z</StatusDate><Source id="1539212" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="973340" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17927">PharmaMar SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="973340" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17927">PharmaMar SA</OwnerCompany><Country id="EU">EU</Country><Indication id="1261">Small-cell lung cancer</Indication><AwardedIndication>Treatment of small cell lung cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-02-26T00:00:00.000Z</MileStoneDate><Source id="2135892" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17927">PharmaMar SA</OwnerCompany><Country id="EU">EU</Country><Indication id="1261">Small-cell lung cancer</Indication><AwardedIndication>Treatment of small cell lung cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2019-01-24T00:00:00.000Z</MileStoneDate><Source id="2113811" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17927">PharmaMar SA</OwnerCompany><Country id="US">US</Country><Indication id="1261">Small-cell lung cancer</Indication><AwardedIndication> Treatment of small cell lung cancer (SCLC)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-08-01T00:00:00.000Z</MileStoneDate><Source id="2064368" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17927">PharmaMar SA</OwnerCompany><Country id="EU">EU</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-10-10T00:00:00.000Z</MileStoneDate><Source id="1339954" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17927">PharmaMar SA</OwnerCompany><Country id="EU">EU</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2012-09-05T00:00:00.000Z</MileStoneDate><Source id="1321660" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17927">PharmaMar SA</OwnerCompany><Country id="US">US</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-08-20T00:00:00.000Z</MileStoneDate><Source id="1319184" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17927">PharmaMar SA</OwnerCompany><Country id="US">US</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-08-20T00:00:00.000Z</MileStoneDate><Source id="1319184" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01701"><Name>RNA polymerase II</Name><SwissprotNumbers/></Target><Target id="PTGT-01817"><Name>TAT protein</Name><SwissprotNumbers><Swissprot>P04326</Swissprot><Swissprot>P04605</Swissprot><Swissprot>P04608</Swissprot><Swissprot>P04609</Swissprot><Swissprot>P04610</Swissprot><Swissprot>P04611</Swissprot><Swissprot>P04612</Swissprot><Swissprot>P04613</Swissprot><Swissprot>P04614</Swissprot><Swissprot>P05905</Swissprot><Swissprot>P05906</Swissprot><Swissprot>P05907</Swissprot><Swissprot>P05908</Swissprot><Swissprot>P05909</Swissprot><Swissprot>P05910</Swissprot><Swissprot>P05911</Swissprot><Swissprot>P05912</Swissprot><Swissprot>P05913</Swissprot><Swissprot>P12453</Swissprot><Swissprot>P12506</Swissprot><Swissprot>P12507</Swissprot><Swissprot>P12508</Swissprot><Swissprot>P12509</Swissprot><Swissprot>P12510</Swissprot><Swissprot>P12511</Swissprot><Swissprot>P12512</Swissprot><Swissprot>P12513</Swissprot><Swissprot>P15835</Swissprot><Swissprot>P16904</Swissprot><Swissprot>P17285</Swissprot><Swissprot>P17759</Swissprot><Swissprot>P18044</Swissprot><Swissprot>P18098</Swissprot><Swissprot>P18804</Swissprot><Swissprot>P19507</Swissprot><Swissprot>P19552</Swissprot><Swissprot>P19553</Swissprot><Swissprot>P19564</Swissprot><Swissprot>P20879</Swissprot><Swissprot>P20880</Swissprot><Swissprot>P20893</Swissprot><Swissprot>P24109</Swissprot><Swissprot>P24738</Swissprot><Swissprot>P35965</Swissprot><Swissprot>P69697</Swissprot><Swissprot>P69698</Swissprot><Swissprot>Q74124</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1015499">Luye Pharma Group Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1041703">Swiss Group for Clinical Cancer Research</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14987">Boryung Pharm Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18440">Myriad Genetics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27906">Zeltia SA</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>6</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1cc2c(c(c1OC)O)[C@@H]3[C@@H]4[C@H]5c6c(c7c(c(c6OC(=O)C)C)OCO7)[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)c9c(c1cc(ccc1[nH]9)OC)CCN8</Smiles><Smiles>C[C@@H](/C=C(\C)/C=C\C=C/C(=O)N[C@H](C(=O)N/C=C\C[C@H](C/C=C(\C)/Cl)OC(=O)N)C(C)(C)C)[C@@H]1CC=C(C(=O)O1)OC</Smiles></StructureSmiles><Deals><Deal id="140624" title="Myriad Genetics to conduct BRCA analysis on patients enrolled for PharmaMar's lurbinectedin phase II study"/><Deal id="162607" title="Boryung to commercialize PharmaMar's oncology drug Aplidin in South Korea         "/><Deal id="235954" title="Chugai to develop and commercialize PharmaMar's PM-1183 for platinum-resistant ovarian cancer, small cell lung cancer and solid tumors in Japan   "/><Deal id="239157" title="STA to distribute PharmaMar's lurbinectedin against cancer in Australia, New Zealand and in 12 Asian countries   "/><Deal id="252268" title="SAKK to conduct phase II clinical study of PharmaMar's lurbinectedin for malignant pleural mesothelioma"/><Deal id="255376" title="Luye Pharma to develop and commercialize PharmaMar’s Zepsyre for small cell lung cancer in China"/></Deals><PatentFamilies><PatentFamily id="1778488" number="WO-2012062920" title="Combination therapy with an antitumor alkaloid"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zeltia SA" id="27906"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>